ERBB2 and breast carcinoma: The authors studied HER2 amplification and drug resistance of lapatinib using Raman spectroscopy in BT474 (HER2+ breast cancer cell), MCF-10A (HER2− control), and HER2+ MCF-10A (HER2+ control) cell lines.